Q2 2022 Nordic Nanovector ASA Earnings Call Transcript
Good morning, ladies and gentlemen. My name is Jan Egberts. I'm the Chairman of the Board of Directors of Nordic Nanovector. Welcome to our second quarterly release and first half of 2022 results. Together with me here are Malene Brondberg, our CFO and Interim CEO; and Lars Nieba, our Chief Technology Officer.
On the first slide, I need to share with you our safe harbor statement, basically about forward-looking statements. I urge you to pay attention to this.
First of all, a quick update. Unfortunately, as all you have heard, is we had to discontinue the PARADIGME clinical study studying Betalutin. The reason, as have been shared before, is the difficulties in enrolling sufficient patients into that study, which made the Board consider where we are and do an interim analysis.
Now the interim analysis was executed by an independent review board, which basically, yes, came to the conclusion and the Board came to the conclusion that the regulatory feasibility of getting this product approved was such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
